Ruoshi Shi; Nikolina Radulovich; Christine Ng; Geoffrey Liu; Hirotsugu Notsuda; Michael Cabanero; Sebastião N. Martins-Filho; Vibha Raghavan; Quan Li; Arvind Singh Mer; Joshua C. Rosen; Ming Li; Yu-Hui Wang; Laura Tamblyn; Nhu‐An Pham; Benjamin Haibe‐Kains; Geoffrey Liu; Nadeem Moghal; Ming‐Sound Tsao · 2019 · Clinical Cancer Research
Paper
PURPOSE: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related deaths worldwide. There is an unmet need to develop novel clinically relevant models of NSCLC to accelerate identification of drug targets and our understanding of the disease. EXPERIMENTAL DESIGN: Thirty surgically resected NSCLC primary patient tissue and 35 previously established patient-derived xenograft (PDX) models were processed for organoid culture establishment. Organoids were histologically and molecularly characterized by cytology and histology, exome sequencing, and RNA-sequencing analysis. Tumorigenicity was assessed through subcutaneous injection of organoids in NOD/SCID mice. Organoids were subjected to drug testing using EGFR, FGFR, and MEK-targeted therapies. RESULTS: We have identified cell culture conditions favoring the establishment of short-term and long-term expansion of NSCLC organoids derived from primary lung patient and PDX tumor tissue. The NSCLC organoids recapitulated the histology of the patient and PDX tumor. They also retained tumorigenicity, as evidenced by cytologic features of malignancy, xenograft formation, preservation of mutations, copy number aberrations, and gene expression profiles between the organoid and matched parental tumor tissue by whole-exome and RNA sequencing. NSCLC organoid models also preserved the sensitivity of the matched parental tumor to targeted therapeutics, and could be used to validate or discover biomarker-drug combinations. CONCLUSIONS: Our panel of NSCLC organoids closely recapitulates the genomics and biology of patient tumors, and is a potential platform for drug testing and biomarker validation.
Analysis
This study establishes and characterizes non-small cell lung cancer (NSCLC) organoid models derived from patient tumors and patient-derived xenografts (PDX) for preclinical drug testing and biomarker validation.
Discovery
Mark T. Kozlowski; Christiana Crook; Hsun Teresa Ku
Fuyin Zheng; Yuminghao Xiao; Hui Liu; Yubo Fan; Ming Dao
Caleb Jensen; Yong Teng
Qirui Wu; Jinfeng Liu; Xiaohong Wang; Lingyan Feng; Jinbo Wu; Xiaoli Zhu; Weijia Wen; Xiuqing Gong
Giovanni Giuseppe Giobbe; Claire Crowley; Camilla Luni; Sara Campinoti; Moustafa Khedr; Kai Kretzschmar; Martina M. De Santis; Elisa Zambaiti; Federica Michielin; Laween Meran; Qianjiang Hu; Gijs J. F. van Son; Luca Urbani; Manfredi Anna; Monica Giomo; Simon Eaton; Davide Cacchiarelli; Vivian Li; Hans Clevers; Paola Bonfanti; Nicola Elvassore; Paolo De Coppi
Kevin Achberger; Christopher Probst; Jasmin Haderspeck; Sylvia Bolz; Julia Rogal; Johanna Chuchuy; Marina Nikolova; Virginia Cora; Lena Antkowiak; Wadood Haq; Nian Shen; Katja Schenke‐Layland; Marius Ueffing; Stefan Liebau; Peter Loskill
Source record